Your session is about to expire
← Back to Search
Procedure
Magnetic Seizure Therapy for Schizophrenia (MAST Trial)
N/A
Waitlist Available
Led By Daniel Blumberger, M.D., MSc.
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients with a DSM-5 diagnosis of Schizophrenia or Schizoaffective Disorder for at least 2 years, as determined by the MINI International Neuropsychiatric Interview - Version 7 (MINI-7.0)
Patients with a BPRS score at baseline of at least moderate severity (>4) on one of the four psychotic items (i.e., hallucinatory behavior, suspiciousness, conceptual disorganization, unusual thought content) or at least 12 on these 4 items combined
Must not have
Patients with any significant neurological disorder or condition likely to be associated with increased intracranial pressure or a space-occupying brain lesion, e.g., cerebral aneurysm
Patients with a concomitant major unstable medical illness
Timeline
Screening 3 weeks
Treatment Varies
Follow Up greater than 8 treatments (2.5 weeks)
Awards & highlights
No Placebo-Only Group
Summary
"This trial will study the benefits and side effects of using Magnetic Seizure Therapy instead of electroconvulsive therapy for treating Schizophrenia that has not responded well to other treatments."
Who is the study for?
This trial is for individuals with Treatment Resistant Schizophrenia, meaning their condition hasn't improved after trying other treatments. Participants should be able to undergo procedures like Magnetic Seizure Therapy (MST) or Electroconvulsive Therapy (ECT).
What is being tested?
The study compares the effectiveness and tolerability of two treatments: Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT), in patients who have not responded well to standard schizophrenia therapies.
What are the potential side effects?
Possible side effects may include confusion, memory problems, headaches, muscle aches or discomfort at the site of treatment. These are common to seizure-inducing therapies but can vary between MST and ECT.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with Schizophrenia or Schizoaffective Disorder for over 2 years.
Select...
My mental health assessment shows moderate to severe symptoms in areas like hallucinations or suspicion.
Select...
I am 18 years old or older.
Select...
I have tried at least 2 antipsychotics for over 6 weeks without success.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have any major brain disorders like aneurysms.
Select...
I have a serious illness that is not stable.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ greater than 8 treatments (2.5 weeks)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~greater than 8 treatments (2.5 weeks)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Brief Psychiatric Rating Scale (BPRS) Response (18-Version)
MATRICS™ Consensus Cognitive Battery (MCCB)
Secondary study objectives
Autobiographical Memory Test (AMT)
Montreal Cognitive Assessment (MoCA)
Scale for Suicidal Ideation (SSI)
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Magnetic Seizure Therapy (MST)Experimental Treatment1 Intervention
MST treatments will be administered using the MagPro MST with Cool TwinCoil.
Group II: Electroconvulsive Therapy (ECT)Active Control1 Intervention
ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Seizure Therapy (MST)
2018
N/A
~190
Find a Location
Who is running the clinical trial?
Centre for Addiction and Mental HealthLead Sponsor
375 Previous Clinical Trials
82,807 Total Patients Enrolled
59 Trials studying Schizophrenia
4,231 Patients Enrolled for Schizophrenia
University of British ColumbiaOTHER
1,481 Previous Clinical Trials
2,494,836 Total Patients Enrolled
15 Trials studying Schizophrenia
1,449 Patients Enrolled for Schizophrenia
Daniel Blumberger, M.D., MSc.Principal InvestigatorCentre for Addiction and Mental Health